

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231 on 30 JANUARY 2003



Patent Application  
Docket No. USF-T150CX  
Serial No. 09/955,174

RECEIVED  
FEB 07 2003  
FISH CENTER 1600/2900

  
Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Applicant(s) : William G. Kerr  
Serial No. : 09/955,174  
Filed : September 19, 2001  
For : Control of NK Cell Function and Survival by Modulation of Ship Activity

#117 Suppl.  
I.D.S.

Assistant Commissioner for Patents  
Washington, D.C. 20231


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

  
Jeff Lloyd  
Patent Attorney

Registration No. 35,589


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

JL/srp

Enclosures as stated above



Approved for use through 10/31/2002. PTO/SB/08A (10/2001)  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/955,174
				Filing Date	September 19, 2001
				First Named Inventor	William G. Kerr
				Art Unit	1614
				Examiner Name	(not yet assigned)
Sheet	1	of	2	Attorney Docket Number	USF-T150CX

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-6,025,198	12-15-2000	Bennet et al.	throughout
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

⊕ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

FEB 07 2003

TECH CENTER 1600/2900  
PTO/SB/08B (10-01)Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1614
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T150CX

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	AKAGI, KIWAMU et al., Cre-mediated comatic site-specific recombination in mice, Nucleic Acids Research, 1997, 25(9):1766-1773, Oxford University Press.	
	R2	LOTZOVA, E. et al., Prevention of Rejection of Allogeneic Bone Marrow Transplants by NK-1.1 Anti Serum, Transplantation, 1983, 35(5):490-494.	
	R3	HELD, WERNER et al., Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection, Journal of Experimental Medicine, 1996 184(5):2037-2041.	
	R4	GHANSAH, TOMAR et al., The Src homology 2 containing inositol phosphatase is vital for the function and homeostatis of Natural Killer cells, FASEB Journal, March 7, 2001, 15(4):A655.	
	R5	KERR, WILLIAM G. et al., Critical Role for SHIP in engraftment of histo-incompatible stem cells, Oncology Research, 2001, 12:285.	
	R6	GHANSAH, TOMAR et al., A role for the SH2-containing inositol phosphatase in the biology of natural killer cells and stem cells, Activating and Inhibitory Immunoglobulin-like Receptors, 2001, 129-140.	
	R7	WANG, JIA WANG et al., Influence of ZSHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation, Science, 295(5562):2094-2097.	
	R8	DESPONTS, CAROLINE et al., MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival, FASEB Journal, March 20, 2002, 16(4):A706.	
	R9	GHANSAH, TOMAR et al., Target disruption of Src homology 2-containing 5' inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells, FASEB Journal, March 20, 2002, 16(4):A706	
	R10		
	R11		
	R12		
	R13		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.